Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Boehringer Ingelheim Identifier:
First received: November 24, 2009
Last updated: December 7, 2016
Last verified: December 2016
Compare safety and efficacy of BIBF 1120 versus sunitinib in patients with advanced RCC and to investigate the effects of BIBF 1120 on the heart rate (HR) corrected QT interval (QTcF).

Condition Intervention Phase
Carcinoma, Renal Cell
Drug: BIBF 1120
Drug: sunitinib
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomised, Open Label, Parallel Group Phase II Study Comparing the Efficacy and Tolerability of BIBF 1120 Versus Sunitinib in Previously Untreated Patients With Renal Cell Cancer

Resource links provided by NLM:

Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • Progression Free Survival at 9 months. [ Time Frame: 9 months of treatment ]
  • For patients treated with with BIBF 1120. Change from baseline to endpoint (day 15) of the QT interval at each point in time QTcF (QT interval corrected by the Frederica formula). [ Time Frame: 9 months of treatment ]

Secondary Outcome Measures:
  • Progression Free survival [ Time Frame: 18 months ]
  • Objective Response [ Time Frame: 36 months ]
  • Duration of Response [ Time Frame: 36 months ]
  • Overall Survival [ Time Frame: 36 months ]
  • Time to treatment failure. [ Time Frame: 36 months ]
  • Time to progression. [ Time Frame: 36 months ]
  • BIBF 1120 patients only: - Change from baseline to Day 1 of QTcF interval at each point in time. - QTcF interval at the time of each patient's maximum BIBF 11230 concentration - Time-averaged QTcF interval over 1-12 hours. [ Time Frame: 15 Days ]
  • Safety Endpoints all patients: Frequency of Adverse Events. -Number and duration of hospital stays due to Adverse Events -Dose-related dose reduction and discontinuation rate -Laboratory parameters graded by CTCAE v3 -PR and QRS intervals of ECG: [ Time Frame: 36 months ]
  • BIBF 1120 patients only: - New onset of QT/QTc>500ms - New onset of QTc>470ms - New onset of QTc>450ms [ Time Frame: 15 days ]

Estimated Enrollment: 99
Study Start Date: December 2009
Estimated Study Completion Date: August 2017
Estimated Primary Completion Date: August 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BIBF 1120
Non-marketed substance: Twice daily oral doses of 200mg BIBF 1120 given continuously.
Drug: BIBF 1120
VEGF inhibitor
Active Comparator: sunitinib
Marketed substance: Once a day oral doses of 50mg sunitinib given in repeated 6 week cycles: 4 weeks active, 2 weeks rest.
Drug: sunitinib
VEGF inhibitor


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  1. Patients with unresectable or metastatic Renal Cell Cancer, who have received no previous systemic anti-cancer treatment.
  2. Histological-confirmed diagnosis of renal cell cancer with clear cell component.
  3. Acceptable renal,liver,cardiovascular,bone marrow and other functions to allow sunitinib/BIBF 1120 treatment.

Exclusion criteria:

  1. Patients unable to tolerate Sunitinib/BIBF 1120 treatment
  2. Treatment with other investigational drugs or participation in another clinical study within the past 4 weeks before start of therapy or concomitantly with this study.
  3. Patients unable to comply with the 1199.26 protocol.
  4. Pregnancy or breast feeding.
  5. Active alcohol or drug abuse.
  6. Women of child bearing potential, or men who are able to father a child, unwilling to use a medically acceptable form of contraception during the study period.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01024920

Boehringer Ingelheim Investigational Site
Pecs, Hungary
Boehringer Ingelheim Investigational Site
Lublin, Poland
Boehringer Ingelheim Investigational Site
Warszawa, Poland
Boehringer Ingelheim Investigational Site
Bucharest, Romania
Boehringer Ingelheim Investigational Site
Craiova, Romania
Boehringer Ingelheim Investigational Site
Cherkasy, Ukraine
Boehringer Ingelheim Investigational Site
Chernivtsi, Ukraine
Boehringer Ingelheim Investigational Site
Dnipropetrovks, Ukraine
Boehringer Ingelheim Investigational Site
Lviv, Ukraine
Boehringer Ingelheim Investigational Site
Uzhgorod, Ukraine
United Kingdom
Boehringer Ingelheim Investigational Site
Cambridge, United Kingdom
Boehringer Ingelheim Investigational Site
Glasgow, United Kingdom
Boehringer Ingelheim Investigational Site
Guildford, United Kingdom
Boehringer Ingelheim Investigational Site
Leeds, United Kingdom
Sponsors and Collaborators
Boehringer Ingelheim
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Boehringer Ingelheim Identifier: NCT01024920     History of Changes
Other Study ID Numbers: 1199.26
2009-009516-44 ( EudraCT Number: EudraCT )
Study First Received: November 24, 2009
Last Updated: December 7, 2016

Additional relevant MeSH terms:
Carcinoma, Renal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors processed this record on April 28, 2017